Home › Companies › IVVD

Invivyd

Market cap $152M 295.6M shares (10-Q, Oct 29, 2026) × $0.513 close Nov 17, 2026

Most recent annual filing: 2026-03-05

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. VMS063 / VBY329 corporate update2H 2026VMS063 / VBY329 corporate update, 2H 2026, routine
  2. VYD2311 / PEMGARDA BLA filing2H 2026/1H 2027VYD2311 / PEMGARDA BLA filing, 2H 2026/1H 2027, notable
  3. IVVD corporate listing updateJan 19, 2027IVVD corporate listing update, Jan 19, 2027, routine
  4. PEMGARDA FDA decisionJun 29, 2027PEMGARDA FDA decision, Jun 29, 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

Adimab Platform · Adimab

Adimab antibody discovery and optimization platform transferred to Invivyd; includes B-cell cloning using Adimab's proprietary yeast cell lines, antibody optimization libraries, trade secrets, protocols and software; used for discovery, engineering and optimization of antiviral mAbs targeting coronaviruses and other infectious diseases

Capital (as filed)

Cash
$126M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$32.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$126M cash, runway mid-2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Invivyd, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Avoid Invivyd (IVVD) — Scientific Deep Dive for PEMGARDA, VYD2311, and the Antibody Pipeline Despite validated science and a well-designed Phase 3, the combination of no issued patents on commercial products, a going-concern opinion, a covenant-locked credit facility, and an EUA expiring June 2027 makes the security uninvestable.
  2. Avoid UPDATE: Invivyd (IVVD) - The Readout That Wasn't DECLARATION's clinical efficacy readout was deferred indefinitely in favor of an accelerated approval path based on antibody titers, worsening the risk profile as the regulatory path now depends on FDA accepting an unendorsed surrogate while cash burn and the EUA cliff remain unchanged.
  3. Avoid UPDATE: Invivyd (IVVD) - "Imminently" Is Not a Date The October titer data slipped again to 'imminently,' cash fell to $126.4M with the EUA cliff and Nasdaq deadline closing in, and none of the three named conditions to move to Watch List have been met.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (20)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 29, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)